[Possibility of transferring patients with type-II diabetes mellitus treated with small doses of sulfonylurea preparations to diet therapy].
Nine patients with diabetes mellitus, type II (6 males and 3 females) were studied. The average duration of the disease was 7.1 years. The patients were perorally treated with glibenclamide (5-10 mg daily). Beta-cellular function was studied with glucagon as well as the peripheral insulin sensitivity of the patients on the background of the peroral treatment and after its two-week discontinuation--on the background of dietetic treatment. No significant difference in beta-cellular function, insulin sensitivity and metabolic compensation was established. Part of the patients with diabetes mellitus, type II, treated with low and medium doses of glibenclamide, could well be compensated only by an adequate diet.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000097:blood; D002908:Chronic Disease; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000178:diet therapy* / Q000188:drug therapy; D005260:Female; D005934:Glucagon; D005905:Glyburide / Q000008:administration & dosage; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*
D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D013453:Sulfonylurea Compounds; D005934:Glucagon; D005905:Glyburide
Vŭzmozhnost za preminavane na dietolechenie u bolni sŭs zakharna bolest tip II, lekuvani s malki dozi sulfonilureĭni preparati.